Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Energy Conservation and Activity Management Training Helps Patients Cope With Treatment-Related Fatigue

June 1, 2002
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 6
Volume 11
Issue 6

PHILADELPHIA-Energy conservation and activity management training (ECAM) reduces fatigue levels and helps patients maintain normal activities despite treatment-related fatigue, Andrea M. Barsevick, RN, DNSc, reported. Dr. Barsevick is director of nursing research and education at Fox Chase Cancer Center in Philadelphia.

PHILADELPHIA—Energy conservation and activity management training (ECAM) reduces fatigue levels and helps patients maintain normal activities despite treatment-related fatigue, Andrea M. Barsevick, RN, DNSc, reported. Dr. Barsevick is director of nursing research and education at Fox Chase Cancer Center in Philadelphia.

"Research on interventions for managing fatigue has been limited to correcting chemotherapy-induced anemia or using aerobic exercise. The purpose of this randomized study was to compare the efficacy of ECAM vs an attentional control, which was nutrition education," Dr. Barsevick said. ECAM was defined as "the deliberate and planned management of one’s personal energy resources to prevent their depletion." It includes delegating, setting priorities, pacing oneself, and planning activities at times of peak energy.

"We found that patients in the ECAM group had lower fatigue intensity (P = .04) and less disruption of activities (P = .01) than the control group," Dr. Barsevick told Oncology News International.

Over time these differences narrowed. Most cancer patients eventually discover ways to conserve their energy, she suggested, but this takes longer in the absence of a patient education program.

Trial Design

The trial included 397 patients with breast, lung, colorectal, prostate, gynecologic, testicular cancer, or lymphoma. Patients were receiving at least 5 to 6 weeks of radiation therapy or at least 3 cycles of chemotherapy, or combined chemoradiotherapy.

Patients were randomized to ECAM or to control groups and were assessed at baseline and at two follow-up points of expected high fatigue (week 6 and 10 of radiation or 48 hours after the second and third chemotherapy cycles). Efficacy was measured with validated measures of fatigue, functional status, negative mood, sleep disturbance, and other side effects of treatment.

Articles in this issue

Gleevec Effective as First-Line Therapy of CML: IRIS Trial
Curcumin May Enhance TRAIL-Induced Cancer Cell Death
Cardiac Exercise Rehabilitation Program Can Be Adapted for Cancer Patients
Advent of HAART Associated With Shift in Causes of Death in HIV-Infected Individuals
Symptom Clusters or Groupings Are Common in Cancer Outpatients
Allogeneic BMT Ups 5-Year EFS in Ph- ALL
HIV-1 Vaccine Proving Safe, Immunogenic in Humans
ACS to Fight Tobacco ‘Pandemic’ Worldwide
Aspirin Helps Prevent Recurrent Large Bowel Adenomas
Side Effects of the Treatment of Ovarian Cancer Can Have Great Impact on Activities of Daily Living
Diagnostic Dilemma
High Levels of Leptin May Contribute to Breast Cancer Risk
Rituximab Post-transplant Improves Survival in B-Cell NHL
Nurses Spot Gaps in Application of Clinical Guidelines for Anemia
The University of Texas M. D. Anderson GI Surgery Nurses Develop Education Program to Improve Satisfaction With Patient-Controlled Analgesia

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

Evaluation and Management of Testicular Cancer After Late Relapse

Evaluation and Management of Testicular Cancer After Late Relapse

Joanna L. Langner, MS;Frederick Millard, MD;Vera Vavinskaya, MD;Haiyan Zhang, MD;Nuphat Yodkhunnatham, MD;Aditya Bagrodia, MD
April 16th 2024
Article

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Andrew J. Armstrong, MD, MSc;Tomasz M. Beer, MD
April 27th 2012
Podcast

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.


Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

RPLND May Reduce Need for Chemo/Radiation for Testicular Seminoma

Russ Conroy
March 24th 2023
Article

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.


Targeted Therapies: A Paradigm Shift in RCC

Targeted Therapies: A Paradigm Shift in RCC

Robert J. Motzer, MD
June 8th 2010
Podcast

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.


Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Regina Barragan-Carrillo, MD;Samantha Mateos-Corella, MD;Carlos Ortiz-Hidalgo, MD;Eva A Izquierdo-Echavarri, MD;Ricardo Castillejos-Molina, MD;Martín Angel;Ignacio Barragan-Arteaga;Thomas W. Flaig, MD;María T. Bourlon, MD, MSc, FASCO
December 17th 2021
Article

In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.


Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Ariana Pelosci
September 29th 2021
Article

Patients with testicular cancer who are treated with platinum-based chemotherapy or radiotherapy have an increased risk of mortality unrealted to their disease.

Related Content

Evaluation and Management of Testicular Cancer After Late Relapse

Evaluation and Management of Testicular Cancer After Late Relapse

Joanna L. Langner, MS;Frederick Millard, MD;Vera Vavinskaya, MD;Haiyan Zhang, MD;Nuphat Yodkhunnatham, MD;Aditya Bagrodia, MD
April 16th 2024
Article

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.


Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Andrew J. Armstrong, MD, MSc;Tomasz M. Beer, MD
April 27th 2012
Podcast

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.


Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

RPLND May Reduce Need for Chemo/Radiation for Testicular Seminoma

Russ Conroy
March 24th 2023
Article

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.


Targeted Therapies: A Paradigm Shift in RCC

Targeted Therapies: A Paradigm Shift in RCC

Robert J. Motzer, MD
June 8th 2010
Podcast

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.


Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Regina Barragan-Carrillo, MD;Samantha Mateos-Corella, MD;Carlos Ortiz-Hidalgo, MD;Eva A Izquierdo-Echavarri, MD;Ricardo Castillejos-Molina, MD;Martín Angel;Ignacio Barragan-Arteaga;Thomas W. Flaig, MD;María T. Bourlon, MD, MSc, FASCO
December 17th 2021
Article

In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.


Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Ariana Pelosci
September 29th 2021
Article

Patients with testicular cancer who are treated with platinum-based chemotherapy or radiotherapy have an increased risk of mortality unrealted to their disease.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.